Share Name Share Symbol Market Type Share ISIN Share Description
Dechra Pharmaceuticals LSE:DPH London Ordinary Share GB0009633180 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +23.00p +1.41% 1,651.00p 1,655.00p 1,657.00p 1,664.00p 1,631.00p 1,636.00p 115,340.00 16:35:24
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 247.6 14.5 14.0 117.9 1,537.84

Dechra Share Discussion Threads

Showing 376 to 394 of 400 messages
Chat Pages: 16  15  14  13  12  11  10  9  8  7  6  5  Older
DateSubjectAuthorDiscuss
05/4/2017
18:23
a little pull back after some profit taking is probably in order. I shall continue to accumulate on any weakness. woody
woodcutter
31/3/2017
22:20
Agreed, Woody, could be a very lucrative deal and one for the long term.
dozey3
31/3/2017
11:24
and a very interesting one for the future.........if the price falls a little I will add to my 3/5 year portfolio.
anley
31/3/2017
07:42
looks like a further quality deal/acquisition http://www.investegate.co.uk/dechra-pharm-plc--dph-/rns/licensing-agreement-and-share-acquisition/201703310700131311B/ woody
woodcutter
30/3/2017
09:05
added to my holding this morning. chart looks strong woody
woodcutter
14/3/2017
10:25
Getting near your £17 ............ but why not think of £20 when they announce another record year.......but not just yet!
anley
02/3/2017
14:16
£17 !
phillis
27/2/2017
10:25
Aviva up thier holding before publication of results!! Think about that........ What a good set of results and more to play for by the management.
anley
27/2/2017
10:12
£16 Still with a head of steam!
phillis
10/2/2017
13:30
Whiskers and Fido rule ok.
steeplejack
27/1/2017
14:38
been accumulating a few times since it broke thro' 1400p woody
woodcutter
17/1/2017
18:12
One reason why this company is a success is that the CEO has been able to create a team which is very able in extracting profits from all the acquisitions. When a share goes up on a day like today then there is lot more good news to come over the coming year. Well done the management ..........
anley
17/1/2017
07:35
Trading UpdateThe Board of Dechra issues the following unaudited Trading Update covering the half year reporting period (the Period) from 1 July to 31 December 2016.Highlights-- Reported Group revenue for the Period increased by approximately 34% at constant exchange rate (CER) (56% at actual exchange rate (AER)).-- Core Group revenue growth, excluding the benefit from acquisitions, was 7% at CER (AER 22%); growth in the core EU business was 6% at CER (AER 20%), and 10% (AER 31%) in North America.-- All acquisition integrations are progressing well with revenue contributions from Genera, Putney, Apex and Brovel being ahead of the Board's expectations.-- Approval by the FDA was achieved for the first major product from the Putney pipeline, a Companion Animal Product (CAP) generic antibiotic, Amoxi-clav.Ian Page, Chief Executive Officer, said:"Our underlying business and acquisitions have performed well, resulting in significant growth in the first half of the 2017 financial year. The Group pipeline has delivered new products and our global presence continues to increase. We remain confident in our strategy, our future prospects and our expectations for full year performance."
steeplejack
21/12/2016
17:24
Bought in to the story today as a one year+ holding............
anley
20/12/2016
08:40
Been buying quite a few recently woody free stock charts from uk.advfn.com
woodcutter
15/12/2016
10:57
perky today
phillis
16/9/2016
11:35
Time they started increasing the dividends imo.
gbh2
16/9/2016
10:41
Apex acquisition (Australia/NZ)and base for Asian expansion.looks very sound.The total consideration for the Acquisition, which is expected is to complete on 14 October 2016, is AUS$55.0 million (£31.3 million). This will be funded from the Group's own cash and debt resources. The acquisition is expected to be earnings enhancing in the first 12 months.
steeplejack
05/9/2016
20:46
IC update: After a strong trading update last month, full-year results from veterinary group Dechra (DPH) are unsurprising, but no less impressive. Revenues and adjusted operating profit are both up by over a fifth and three acquisitions completed in the period have enhanced the outlook. Shares are up 3 per cent this morning and we continue to see an upside. Buy. HTTP://www.investorschronicle.co.uk/2016/09/05/shares/news-and-analysis/news-tips-marks-spencer-cambria-automobiles-carr-s-plus-more-l8iOh1CdCyFf8p7P28zy0J/article.html
philanderer
Chat Pages: 16  15  14  13  12  11  10  9  8  7  6  5  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20170426 00:15:42